Paul-Ehrlich-Institut, Paul-Ehrlich-Straße 51-59, D-63225 Langen, Germany1
Author for correspondence: Klaus Boller. Fax +49 6103 771234. e-mail bolkl{at}pei.de
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() |
---|
![]() |
Main text |
---|
![]() ![]() ![]() ![]() |
---|
Virus particles with a morphology similar to HTDV have been observed budding from the syncytial layer of full-term human placentas (Kalter et al., 1973 ; Vernon et al., 1974
), although they have not yet been unequivocally identified as HTDV/HERV-K. Viral proteins have been detected in biopsies of seminomas (Sauter et al., 1995
), and functional viral proteases (Schommer et al., 1996
) as well as reverse transcriptase (Berkhout et al., 1999
) have been demonstrated in vitro after the expression of cloned sequences. The frequent presence of antibodies specific for HTDV/HERV-K proteins in patients suffering from testicular tumours (Sauter et al., 1995
; Boller et al., 1997
) provides indirect evidence of expression in vivo. However, apart from the expression of HTDV/HERV-K proteins in teratocarcinoma cell lines, testicular tumours and most probably in the placenta, their presence in other neoplastic or normal tissues has not been demonstrated. As with endogenous animal retroviruses, the possible involvement of HERV in tumour diseases or autoimmune disorders has been suggested (Urnovitz & Murphy, 1996
; Löwer, 1999
). Furthermore, the involvement of an endogenous retrovirus sequence, IDDMK1,222, with a sequence similarity to HERV-K in type I diabetes has been claimed recently (Conrad et al., 1997
), but could not be confirmed (Löwer et al., 1998
). A beneficial role of HERV in humans has also been discussed (Venables et al., 1995
; Harris, 1998
). However, direct evidence for a biological function of HTDV/HERV-K has yet to be produced.
Between 25 and 50 different HERV-K sequences are present in the human genome (Tönjes et al., 1996 ) and open reading frames for all three structural protein genes have been cloned from human genomic libraries or from expression libraries of human teratocarcinoma cells. It is not clear whether they originate from a unique provirus because no completely intact replication-competent virus genome has yet been characterized (Tönjes et al., 1999
). This raises the question of whether the virus particles observed in teratocarcinoma cell lines are encoded by one or several HERV-K proviruses and whether all cell lines producing HTDV have identical active sequences. To investigate the possibility of differential HERV-K provirus expression, we studied the morphology and protein banding pattern of HTDV/HERV-K produced by different human germ cell tumour cell lines.
For these studies, six human teratocarcinoma cell lines were examined: GH (Löwer et al., 1984 ) and Tera-1 cells (Fogh & Trempe, 1975
), which are both known to produce HTDV/HERV-K particles (Boller et al., 1997
); NCCIT (Teshima et al., 1988
) and 2102Ep cells (Andrews et al., 1980
); and Tera-2 (Fogh & Trempe, 1975
) and PA-1 cells (Zeuthen et al., 1980
) as virus-negative controls. GH cell lines were established in our institute (Löwer et al., 1984
). NCCIT and 2102Ep cell lines were kindly provided by H.-J. Schmoll (Halle, Germany) and the others were purchased from the ATCC. To detect virus particles and proteins, we used various antibodies specific for HTDV: (i) the HTDV/HERV-K/Gag-specific monoclonal antibody HERMA-1, which was produced by immunizing BALB/c mice with the membrane fraction of GH cells; (ii) a goat serum that was raised against recombinant HERV-K/Gag and kindly provided by R. Tönjes (Boller et al., 1997
); and (iii) a serum from a teratocarcinoma patient that was previously shown to react with HTDV. For immunofluorescence studies, this last antibody was preabsorbed with recombinant HERV-K/Gag protein in order to leave it specific for the putative viral Env protein (Boller et al., 1997
). All three antibodies reacted with the cell lines GH, Tera-1 and 2102Ep in immunofluorescence assays, whereas no reaction was seen with the HERV-K-negative teratocarcinoma cell lines, Tera-2 and PA-1 (data not shown). Surprisingly, only the Gag-specific antibodies and not the Env-specific human serum reacted with the human teratocarcinoma cell line NCCIT. The particulate staining pattern of all three antibodies was located at the cell surface of positive cell lines, as would be expected for C-type virus staining. Immunofluorescence double-labelling experiments with Gag- and Env-specific antibodies on GH, Tera-1 and 2102Ep cells clearly showed a colocalization, indicating that both proteins are incorporated into virus particles (results not shown).
In the three cell lines that were reactive with anti-HTDV/HERV-K antibodies in immunofluorescence analyses, retrovirus-like particles of the HTDV type described earlier could be detected by electron microscopy on ultra-thin sections performed according to standard methods. Virus particles were most easily found in GH cells, where groups of more than 10 virions were frequent (Fig. 1a). The cell line producing the smallest number of virus particles was the Tera-1 cell line, where single virus particles could only occasionally be observed (Fig. 1b
, c
). Virus production in NCCIT and 2102Ep cells was moderate, with single as well as small groups of virus particles being found within some minutes of examination. When comparing virus particle morphology, particular attention was paid to the presence of surface spikes (representing the envelope glycoprotein) and free mature virus particles with condensed cores, which are typical for infectious retroviruses in the virus maturation stage (Frank et al., 1978
). During earlier studies using GH cells, virus particles with spikes were not found and free mature virus particles were only rarely observed. This was confirmed for both GH and Tera-1 cells (Fig. 1
). In contrast, many virus particles with spikes were clearly observed budding from 2102Ep cells (Fig. 2
), with about 1020% of virions showing prominent surface projections of equal length and structure. While free mature virus particles with condensed cores were hardly seen in GH, Tera-1 and 2102Ep cells, a significant proportion of these mature virions was found in the NCCIT cell line. These virus particles usually occurred in groups and were often associated with budding virus particles showing the classical HTDV morphology, i.e. exhibiting the typical structure of a mature mammalian C-type retrovirus with a centrally located polygonal core (Fig. 3b
, d
). To confirm that the free mature virus particles in NCCIT cells did not represent a retrovirus of different origin (endogenous or exogenous), we performed immunoelectron microscopy on freeze-substituted Lowicryl-embedded cells using goat antiserum specific for recombinant HERV-K/Gag, where bound antibodies were detected with anti-goat antibodies labelled with 10 nm colloidal gold. Virions with condensed cores were found to be labelled as efficiently as the immature virus particles or virus particles budding at the cytoplasmic membrane (Fig. 3e
, f
).
|
|
|
To investigate whether these observations could be confirmed at the protein level, immunoblotting analyses (Boller et al., 1997 ) were performed using the different antibodies available. The monoclonal antibody HERMA-1 (specific for the HTDV/HERV-K/Gag protein) showed only minor differences between whole cell lysates of the HTDV-positive cell lines (Fig. 4
). In Tera-1 and 2102Ep cells, however, only one major band with a molecular mass of 80 kDa, corresponding to the Gag precursor protein, was seen. In GH and NCCIT cells, an additional prominent band with a molecular mass of 30 kDa was observed, representing the cleaved Gag of HTDV/HERV-K. Using the teratocarcinoma patient serum, the same bands were seen together with bands representing the putative 90 kDa HERV-K Env protein, which was observed in GH, Tera-1 and 2102Ep cells but not in NCCIT cells. Interestingly, in Tera-1 and 2102Ep cells, the band representing the Gag protein was consistently less prominent than the band thought to be the Env protein. In GH cells, however, both viral proteins were detectable in approximately equal amounts.
|
The production of morphologically distinct retrovirus-like particles from different human teratocarcinoma cell lines has been observed previously (Bronson et al., 1984 ). According to our results, these viruses were probably just different forms of HTDV/HERV-K virions. This study is the first to report the existence of free and mature HTDV particles, although this type of HTDV/HERV-K (as observed in the NCCIT cell line) lacks the Env protein and therefore cannot be infectious, given the role played by Env in cellular binding and uptake. There would therefore appear to be a selection pressure for the production of non-infectious viruses.
In conclusion, the levels of transcription (Medstrand et al., 1992 ; Li et al., 1995
), translation and virus particle formation (this work) clearly indicate that various HERV-K proviruses are expressed. As a completely intact replication-competent sequence probably does not exist, it has been speculated that HTDV/HERV-K virus particles might originate by complementation of transcripts from different proviruses (Löwer et al., 1996
); Li et al. (1995
) observed that different HERV-K sequences can be expressed in a single teratocarcinoma cell line and the results reported here would support this hypothesis.
In two of the cell lines studied here, two types of particle were observed. Although this does not demonstrate unequivocally that different proviruses are active (the same sequence could be responsible for different morphotypes as immature and mature virus particles), there seems to be a heterogeneity in virus expression. However, if several proviruses are transcribed in one cell and can participate in virus particle formation, phenotypic mixing could occur and eventually lead to infectious virions. It would therefore be worthwhile to look further for signs of infection by HTDV/HERV-K.
![]() |
Acknowledgments |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() |
---|
Berkhout, B., Jebbink, M. & Zsiros, J.(1999). Identification of an active reverse transcriptase enzyme encoded by a human endogenous HERV-K retrovirus. Journal of Virology 73, 2365-2375.
Boller, K., Frank, H., Löwer, J., Löwer, R. & Kurth, R.(1983). Structural organization of unique retrovirus-like particles budding from human teratocarcinoma cell lines. Journal of General Virology 64, 2549-2559.[Abstract]
Boller, K., König, H., Sauter, M., Mueller-Lantzsch, N., Löwer, R., Löwer, J. & Kurth, R.(1993). Evidence that HERV-K is the endogenous retrovirus sequence that codes for the human teratocarcinoma-derived retrovirus HTDV. Virology 196, 349-353.[Medline]
Boller, K., Janssen, O., Schuldes, H., Tönjes, R. R. & Kurth, R.(1997). Characterization of the antibody response specific for the human endogenous retrovirus HTDV/HERV-K. Journal of Virology 71, 4581-4588.[Abstract]
Bronson, D. L., Fraley, E. E., Fogh, J. & Kalter, S. S.(1979). Induction of retrovirus particles in human testicular tumor (Tera-1) cell cultures: an electron microscopic study. Journal of the National Cancer Institute 63, 337-339.[Medline]
Bronson, D. L., Saxinger, W. C., Ritzi, D. M. & Fraley, E. E.(1984). Production of virions with retrovirus morphology by human embryonal carcinoma cells in vitro. Journal of General Virology 65, 1043-1051.[Abstract]
Conrad, B., Weissmahr, R. N., Boni, J., Arcari, R., Schupbach, J. & Mach, B.(1997). A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. AIDS Research and Human Retroviruses 90, 303-313.
Fogh, J. & Trempe, G. (1975). In Human Tumor Cells In Vitro, pp. 115138. Edited by J. Fogh. New York: Plenum Press.
Frank, H., Schwarz, H., Graf, T. & Schafer, W.(1978). Properties of mouse leukemia viruses. XV. Electron microscopic studies on the organization of Friend leukemia virus and other mammalian C-type viruses. Zeitschrift für Naturforschung Section C Biosciences 33, 124-138.[Medline]
Harris, J. R.(1998). Placental endogenous retrovirus (ERV): structural, functional, and evolutionary significance. Bioessays 20, 307-316.[Medline]
Kalter, S. S., Helmke, R. J., Heberling, R. L., Panigel, M., Fowler, A. K., Strickland, J. E. & Hellman, A.(1973). Brief communication: C-type particles in normal human placentas. Journal of the National Cancer Institute 50, 1081-1084.[Medline]
Kurth, R., Löwer, R., Löwer, J., Harzmann, R., Pfeiffer, R., Schmidt, C. G., Fogh, J. & Frank, H. (1980). In Cold Spring Harbor Conferences On Cell Proliferation, pp. 835846. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
Li, M. D., Bronson, D. L., Lemke, T. D. & Faras, A. J.(1995). Restricted expression of new HERV-K members in human teratocarcinoma cells. Virology 208, 733-741.[Medline]
Löwer, R.(1999). The pathogenic potential of endogenous retroviruses: facts and fantasies. Trends in Microbiology 7, 350-356.[Medline]
Löwer, R., Löwer, J., Frank, H., Harzmann, R. & Kurth, R.(1984). Human teratocarcinomas cultured in vitro produce unique retrovirus-like viruses. Journal of General Virology 65, 887-898.[Abstract]
Löwer, R., Boller, K., Hasenmaier, B., Korbmacher, C., Mueller-Lantzsch, N., Löwer, J. & Kurth, R.(1993). Identification of human endogenous retroviruses with complex mRNA expression and particle formation. Proceedings of the National Academy of Sciences, USA 90, 4480-4484.[Abstract]
Löwer, R., Löwer, J. & Kurth, R.(1996). The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proceedings of the National Academy of Sciences, USA 93, 5177-5184.
Löwer, R., Tönjes, R. R., Boller, K., Denner, J., Kaiser, B., Phelps, R. C., Löwer, J., Kurth, R., Badenhoop, K., Donner, H., Usadel, K. H., Miethke, T., Lapatschek, M. & Wagner, H.(1998). Development of insulin-dependent diabetes mellitus does not depend on specific expression of the human endogenous retrovirus HERV-K. AIDS Research and Human Retroviruses 95, 11-14.
Medstrand, P., Lindeskog, M. & Blomberg, J.(1992). Expression of human endogenous retroviral sequences in peripheral blood mononuclear cells of healthy individuals. Journal of General Virology 73, 2463-2466.[Abstract]
Sauter, M., Schommer, S., Kremmer, E., Remberger, K., Dolken, G., Lemm, I., Buck, M., Best, B., Neumann-Haefelin, D. & Mueller-Lantzsch, N.(1995). Human endogenous retrovirus K10: expression of Gag protein and detection of antibodies in patients with seminomas. Journal of Virology 69, 414-421.[Abstract]
Schommer, S., Sauter, M., Kräusslich, H.-G., Best, B. & Mueller-Lantzsch, N.(1996). Characterization of the human endogenous retrovirus K proteinase. Journal of General Virology 77, 375-379.[Abstract]
Teshima, S., Shimosato, Y., Hirohashi, S., Tome, Y., Hayashi, I., Kanazawa, H. & Kakizoe, T.(1988). Four new human germ cell tumor cell lines. Laboratory Investigation 59, 328-336.[Medline]
Tönjes, R. R., Löwer, R., Boller, K., Denner, J., Hasenmaier, B., Kirsch, H., König, H., Korbmacher, C., Limbach, C., Lugert, R., Phelps, R. C., Scherer, J., Thelen, K., Löwer, J. & Kurth, R. (1996). HERV-K: the biologically most active human endogenous retrovirus family. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 13 (Suppl. 1), S261267.[Medline]
Tönjes, R. R., Czauderna, F. & Kurth, R.(1999). Genome-wide screening, cloning, chromosomal assignment, and expression of full-length human endogenous retrovirus type K. Journal of Virology 73, 9187-9195.
Urnovitz, H. B. & Murphy, W. H.(1996). Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease. Clinical Microbiology Reviews 9, 72-99.[Abstract]
Venables, P. J., Brookes, S. M., Griffiths, D., Weiss, R. A. & Boyd, M. T.(1995). Abundance of an endogenous retroviral envelope protein in placental trophoblasts suggests a biological function. Virology 211, 589-592.[Medline]
Vernon, M. L., McMahon, J. M. & Hackett, J. J.(1974). Additional evidence of type-C particles in human placentas. Journal of the National Cancer Institute 52, 987-989.[Medline]
Zeuthen, J., Norgaard, J. O., Avner, P., Fellous, M., Wartiovaara, J., Vaheri, A., Rosen, A. & Giovanella, B. C.(1980). Characterization of a human ovarian teratocarcinoma-derived cell line. International Journal of Cancer 25, 19-32.
Received 23 August 2000;
accepted 24 November 2000.